使用重组人促红细胞生成素治疗肾性贫血：实用指南及临床算法
Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm.
作者信息
Macdougall I C, Hutton R D, Cavill I, Coles G A, Williams J D
机构信息
Institute of Nephrology, University of Wales College of Medicine, Cardiff.
出版信息
BMJ. 1990 Mar 10;300(6725):655-9. doi: 10.1136/bmj.300.6725.655.
Abstract
Treatment with erythropoietin is highly effective and beneficial if given with care. In view of its cost, however, it is essential to exclude and treat other causes of anaemia before considering using this hormone. After treatment is started the important points for success are regular review of iron availability state combined with a slow correction of the anaemia. Failure of response requires a thorough search for a possible cause, which should be corrected before considering an increased dose of the hormone. Regular monitoring for potential complications, particularly a rise in blood pressure, is required.
摘要
谨慎使用促红细胞生成素进行治疗非常有效且有益。然而，鉴于其成本，在考虑使用这种激素之前，排除并治疗其他贫血原因至关重要。开始治疗后，成功的关键在于定期复查铁的供应状况并缓慢纠正贫血。治疗无反应时，需要彻底寻找可能的原因，在考虑增加激素剂量之前应先予以纠正。需要定期监测潜在并发症，尤其是血压升高。
相似文献
1
Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm.使用重组人促红细胞生成素治疗肾性贫血：实用指南及临床算法
BMJ. 1990 Mar 10;300(6725):655-9. doi: 10.1136/bmj.300.6725.655.
2
[Is the index of response to erythropoietin (IRE) a good marker of adequate dialysis?].
Nefrologia. 2001;21(6):606-7.
3
Treatment of the anaemia of chronic renal failure with recombinant human erythropoietin.重组人促红细胞生成素治疗慢性肾衰竭贫血
Drugs. 1989 Sep;38(3):342-5. doi: 10.2165/00003495-198938030-00002.
4
[Therapy of renal anemia with recombinant human erythropoietin].重组人促红细胞生成素治疗肾性贫血
Dtsch Med Wochenschr. 1988 Jan 29;113(4):125-9. doi: 10.1055/s-2008-1067605.
5
Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously.静脉注射铁剂纠正了肾性贫血对促红细胞生成素治疗反应不佳的情况。
BMJ. 1989 Jul 15;299(6692):157-8. doi: 10.1136/bmj.299.6692.157.
6
Occult infection and resistance of anaemia to rHuEpo therapy in renal failure.
Nephrol Dial Transplant. 1990;5(3):232-4. doi: 10.1093/ndt/5.3.232.
7
Practical guidelines for the use of NESP in treating renal anaemia.
Nephrol Dial Transplant. 2001;16 Suppl 3:22-8. doi: 10.1093/ndt/16.suppl_3.22.
8
Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose.残余肾大鼠模型中重组人促红细胞生成素治疗的肾脏风险效益决定因素——高血压、贫血、炎症和药物剂量。
Clin Exp Pharmacol Physiol. 2016 Mar;43(3):343-54. doi: 10.1111/1440-1681.12541.
9
Management of the anaemia of chronic renal failure with recombinant erythropoietin.重组促红细胞生成素治疗慢性肾衰竭贫血
Q J Med. 1989 Dec;73(272):1093-101.
10
Haemoglobin targets: we were wrong, time to move on.血红蛋白靶点：我们错了，是时候向前看了。
Lancet. 2007 Feb 3;369(9559):346-50. doi: 10.1016/S0140-6736(07)60165-2.
引用本文的文献
1
Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis.比较 ESA 生物类似药与原研药在慢性肾脏病成人患者中的疗效和安全性：系统评价和荟萃分析。
J Nephrol. 2018 Jun;31(3):321-332. doi: 10.1007/s40620-017-0419-5. Epub 2017 Jun 23.
2
Critical Realism and Empirical Bioethics: A Methodological Exposition.批判实在论与实证生物伦理学：一种方法论阐述
Health Care Anal. 2017 Sep;25(3):191-211. doi: 10.1007/s10728-015-0290-2.
3
Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.促红细胞生成素用于治疗成人慢性肾脏病贫血：一项网状Meta分析
Cochrane Database Syst Rev. 2014 Dec 8;2014(12):CD010590. doi: 10.1002/14651858.CD010590.pub2.
4
The importance of serum transferrin receptor level in the diagnosis of functional iron deficiency due to recombinant human erythropoietin treatment in haemodialysis patients.血清转铁蛋白受体水平在血液透析患者重组人促红细胞生成素治疗所致功能性缺铁诊断中的重要性。
Int Urol Nephrol. 1998;30(5):645-51. doi: 10.1007/BF02550560.
5
Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure.β-促红细胞生成素。其药理学特性及在治疗慢性肾衰竭相关性贫血中的临床应用综述。
Drugs. 1996 Feb;51(2):299-318. doi: 10.2165/00003495-199651020-00008.
6
Resistance to recombinant human erythropoietin due to aluminium overload and its reversal by low dose desferrioxamine therapy.铝过载导致对重组人促红细胞生成素产生耐药性，低剂量去铁胺疗法可使其逆转。
Postgrad Med J. 1993 Feb;69(808):124-8. doi: 10.1136/pgmj.69.808.124.
7
Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients.促红细胞生成素α。关于其在治疗与肾衰竭和慢性病相关的贫血中的临床疗效及其在外科手术患者中的应用的综述。
Drugs Aging. 1995 Aug;7(2):131-56. doi: 10.2165/00002512-199507020-00007.
8
Controversies in determination of epoetin (recombinant human erythropoietin) dosages.
Clin Pharmacokinet. 1992 Jun;22(6):409-15. doi: 10.2165/00003088-199222060-00001.
9
Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease.低剂量皮下注射促红细胞生成素对终末期肾病贫血患者的成本效益
BMJ. 1992 Feb 22;304(6825):474-7. doi: 10.1136/bmj.304.6825.474.
本文引用的文献
1
THE DIAGNOSIS OF IRON DEFICIENCY ANEMIA.缺铁性贫血的诊断
Am J Med. 1964 Jul;37:62-70. doi: 10.1016/0002-9343(64)90212-8.
2
Effect of parathyroid hormone on erythropoiesis.甲状旁腺激素对红细胞生成的影响。
J Clin Invest. 1981 May;67(5):1263-9. doi: 10.1172/jci110154.
3
Influence of continuous ambulatory peritoneal dialysis on the anemia of endstage renal disease.
Kidney Int. 1983 May;23(5):744-8. doi: 10.1038/ki.1983.88.
4
Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoiesis in renal failure.血液透析和持续性非卧床腹膜透析对肾衰竭患者红细胞生成的影响。
Kidney Int. 1984 Feb;25(2):430-6. doi: 10.1038/ki.1984.35.
5
Estimates of iron sufficiency in the US population.美国人群铁充足情况的估计。
Blood. 1986 Sep;68(3):726-31.
6
Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.用重组人促红细胞生成素纠正终末期肾病贫血。一项I期和II期联合临床试验的结果。
N Engl J Med. 1987 Jan 8;316(2):73-8. doi: 10.1056/NEJM198701083160203.
7
Recombinant human erythropoietin: implications for nephrology.
Am J Kidney Dis. 1988 Mar;11(3):203-9. doi: 10.1016/s0272-6386(88)80150-1.
8
Blood rheology and hypertension in hemodialysis patients treated with erythropoietin.接受促红细胞生成素治疗的血液透析患者的血液流变学与高血压
Am J Nephrol. 1988;8(6):449-53. doi: 10.1159/000167652.
9
Working capacity is increased following recombinant human erythropoietin treatment.
Kidney Int. 1988 Oct;34(4):525-8. doi: 10.1038/ki.1988.213.
10
Treatment of the anemia of predialysis patients with recombinant human erythropoietin: a randomized, placebo-controlled trial.重组人促红细胞生成素治疗透析前患者贫血的随机安慰剂对照试验。
Am J Med Sci. 1988 Sep;296(3):171-9. doi: 10.1097/00000441-198809000-00005.
Zotero 插件